Inhalable Drugs Market Size, Share & Trends Analysis Report By Product (Aerosol, Dry Powder Formulation, Spray), By Application (Respiratory & Non-Respiratory Diseases), And Segment Forecasts, 2019 - 2026

Published: Oct, 2019 | Pages: 80 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global inhalable drugs market size is expected to reach over USD 40.6 billion by 2026, according to a new report by Grand View Research, Inc., registering a CAGR of 6.3% over the forecast period. Rising prevalence of respiratory diseases and increasing geriatric population are some of the key factors expected to drive the market. Chronic obstructive pulmonary disease (COPD) is a life-threatening respiratory ailments, which is projected to become the third leading cause of death globally. This will increase the demand for inhalable drugs.

According to the Global Burden of Disease study, in 2016, 251 million cases of COPD were reported worldwide. Hence, the need for developing new inhalable drugs has increased. For instance, in January 2019, Verona Pharma received WHO approval for developing Ensifentrine indicated for COPD, which has completed Phase II of clinical trials.

Advancements in inhalable drugs is anticipated to propel the inhalable drugsmarket. Nanoparticles are studied for the development of advanced inhalation drugs. For instance, in April 2019, a scientist from Queensland University of Technology conducted a research using chitosan nanoparticles loaded with inhalation powder for lung cancer. These nanoparticles can easily penetrate the lower respiratory tract and can diffuse into the bloodstream.

Rising prevalence of non-respiratory diseases such as diabetes and Parkinson's diseases is also expected to drive the market. Therefore, manufacturers are developing cost-effective and innovative inhalable drugs. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for diabetic patients.

Presence of strong pipeline drugs is considered to be one of the major factors estimated to boost the market growth. There are more than 220 ongoing projects under clinical trials globally. For instance, GlaxoSmithKline's triple combination therapy of Fluticasone Furoate/Vilanterol/Umeclidinium Bromide to treat asthma is in Phase III and is likely to be launched during the forecast period.

Companies are undergoing strategic initiatives such as collaborations, mergers and acquisitions, partnerships, and awareness programs to widen their product portfolio and gain a stronger foothold in the market. For instance, in July 2019, Cipla, Inc. entered into a joint venture with Shanghai-based Jiangsu Acebright Pharmaceuticals to establish a company in the People's Republic of China to manufacture respiratory products.

Further key findings from the study suggest:

• By product, the dry powder formulation segment dominated the market for inhalable drugs in 2018 owing to benefits such as low density and ability to disperse easily through inhalers

• Based on application, respiratory diseases held the largest market share in terms of revenue in 2018, due to high prevalence of asthma and COPD. The non-respiratory diseases segment is growing at a rapid pace owing to the high opportunity in management of various neurological disorders

• North America held the leading position in the global inhalable drugsmarket for inhalable drugs in 2018, driven by established pharmaceutical industry and healthcare facilities and growing awareness about the use of inhalers. The Asia Pacific market is projected to exhibit the fastest growth during the forecast period.

• Key players in this industry include AstraZeneca; Vectura, Cipla Inc.; GlaxoSmithKline; Novartis; Mundipharma; Boehringer Ingelheim International GmbH; and Mylan.

 Table of Contents

Chapter 1 Methodology and Scope
                 1.1 Research Methodology
                 1.2 Research Scope and Assumptions
                 1.3 List of Abbreviations

Chapter 2 Executive Summary
                 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope
                 3.1 Market Segmentation

Chapter 4 Market Definitions

Chapter 5 Industry Outlook
                 5.1 Market Driver Analysis
                     5.1.1 Rising prevalence of respiratory and non-respiratory diseases
                     5.1.2 Rising geriatric population
                     5.1.3 advancements IN therapies
                 5.2 Market Restraint Analysis
                     5.2.1 Stringent regulations
                     5.2.2 Availability of alternative therapy
                 5.3 Key Opportunities Prioritized

Chapter 6 Business Environment Analysis
                 6.1 SWOT analysis; by factor (Political & legal, economic, and technological)
                 6.2 Porter's five forces analysis
                 6.3 Major Deals & Strategic Alliances
                     6.3.1 Joint Ventures
                     6.3.2 Mergers and Acquisition
                     6.3.3 Licensing and Partnership
                     6.3.4 Technological Collaborations
                     6.3.5 Strategic Divestment
                     6.3.6 Market Entry Strategies
                 6.4 Respiratory Diseases Prevalence
                     6.4.1 Asthma
                     6.4.2 Chronic Obstructive Pulmonary Disease
                     6.4.3 Pulmonary Fibrosis
                     6.4.4 Cystic Fibrosis
                     6.4.5 Allergic Rhinitis (Hay fever)
                 6.5 Top Inhalable Drugs
                 6.6 Pipeline Drugs

Chapter 7 Inhalable Drugs Market: Product Estimates & Trend Analysis
                 7.1 Inhalable Drugs Market: Product Movement Analysis
                     7.1.1 Aerosol
                         7.1.1.1 Aerosol inhalable drugs market, 2014 - 2026 (USD Million)
                     7.1.2 Dry powder formulation
                         7.1.2.1 Dry powder formulation inhalable drugs market, 2014 - 2026 (USD Million)
                     7.1.3 Spray
                         7.1.3.1 Spray inhalable drugs market, 2014 - 2026 (USD Million)

Chapter 8 Inhalable Drugs Market: Application Estimates & Trend Analysis
                 8.1 Inhalable Drugs Market: Application Movement Analysis
                     8.1.1 Respiratory diseases
                         8.1.1.1 Respiratory diseases inhalable drugs market, 2014 - 2026 (USD Million)
                     8.1.2 Non-respiratory diseases
                         8.1.2.1 Non-Respiratory diseases inhalable drugs market, 2014 - 2026 (USD Million)

Chapter 9 Inhalable Drugs Market: Regional Estimates & Trend Analysis, by Product, Application
                 9.1 Inhalable Drugs Market: Regional Movement Analysis
                 9.2 North America
                     9.2.1 North America inhalable drugs market estimates and forecasts, 2014 - 2026 (USD Million)
                     9.2.2 U.S.
                         9.2.2.1 U.S. inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.2.3 Canada
                         9.2.3.1 Canada inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                 9.3 Europe
                     9.3.1 Europe inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.3.2 Germany
                         9.3.2.1 Germany inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.3.3 U.K.
                         9.3.3.1 U.K. inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.3.4 France
                         9.3.4.1 France inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.3.5 Italy
                         9.3.5.1 Italy inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.3.6 Spain
                         9.3.6.1 Spain inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                 9.4 Asia Pacific
                     9.4.1 Asia Pacific inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.4.2 Japan
                         9.4.2.1 Japan inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.4.3 China
                         9.4.3.1 China inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.4.4 India
                         9.4.4.1 India inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.4.5 South Korea
                         9.4.5.1 South Korea inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                 9.5 Latin America
                     9.5.1 Latin America inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.5.2 Brazil
                         9.5.2.1 Brazil inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.5.3 Mexico
                         9.5.3.1 Mexico inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.5.4 Argentina
                         9.5.4.1 Argentina inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                 9.6 Middle East & Africa
                     9.6.1 MEA inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.6.2 South Africa
                         9.6.2.1 South Africa inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.6.3 Saudi arabia
                         9.6.3.1 Saudi Arabia inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)
                     9.6.4 UAE
                         9.6.4.1 UAE inhalable drugs market estimate and forecasts, 2014 - 2026 (USD Million)

Chapter 10 Company Profile
                 10.1 Strategy Framework
                 10.2 Company Profiles
                     10.2.1 GlaxoSmithKline plc
                         10.2.1.1 Company overview
                         10.2.1.2 Financial performance
                         10.2.1.3 Product benchmarking
                         10.2.1.4 Strategic initiatives
                     10.2.2 AstraZeneca
                         10.2.2.1 Company overview
                         10.2.2.2 Financial performance
                         10.2.2.3 Product benchmarking
                         10.2.2.4 Strategic initiatives
                     10.2.3 Boehringer Ingelheim International GmbH
                         10.2.3.1 Company overview
                         10.2.3.2 Financial performance
                         10.2.3.3 Product benchmarking
                         10.2.3.4 Strategic initiatives
                     10.2.4 Vectura Group plc
                         10.2.4.1 Company overview
                         10.2.4.2 Financial performance
                         10.2.4.3 Product benchmarking
                         10.2.4.4 Strategic initiatives
                     10.2.5 Pfizer Inc.
                         10.2.5.1 Company overview
                         10.2.5.2 Financial performance
                         10.2.5.3 Product benchmarking
                     10.2.6 Merck & Co., Inc.
                         10.2.6.1 Company overview
                         10.2.6.2 Financial performance
                         10.2.6.3 Product benchmarking
                     10.2.7 Mylan N.V.
                         10.2.7.1 Company overview
                         10.2.7.2 Financial performance
                         10.2.7.3 Product benchmarking
                         10.2.7.4 Strategic initiatives
                     10.2.8 Teva Pharmaceutical Industries Ltd.
                         10.2.8.1 Company overview
                         10.2.8.2 Financial performance
                         10.2.8.3 Product benchmarking
                         10.2.8.4 Strategic initiatives
                     10.2.9 Sunovion Pharmaceuticals Inc. (SUMITOMO DAINIPPON PHARMA)
                         10.2.9.1 Company overview
                         10.2.9.2 Financial performance
                         10.2.9.3 Product benchmarking
                         10.2.9.4 Strategic initiatives
                     10.2.10 Novartis AG
                         10.2.10.1 Company overview
                         10.2.10.2 Financial performance
                         10.2.10.3 Product benchmarking
                         10.2.10.4 Strategic initiatives
                     10.2.11 Cipla Inc.
                         10.2.11.1 Company overview
                         10.2.11.2 Financial performance
                         10.2.11.3 Product benchmarking
                         10.2.11.4 Strategic initiatives

List of Tables

Table 1 North America Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 2 North America Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 3 U.S. Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 4 U.S. Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 5 Canada Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 6 Canada Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 7 Europe Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 8 Europe Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 9 Germany Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 10 Germany Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 11 U.K. Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 12 U.K. Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 13 France Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 14 France Inhalable Drugs Market, By Application, 2014 - 2026 (USD Million)
Table 15 Italy Inhalable DrugsMarket, By Product, 2014 - 2026 (USD Million)
Table 16 Italy Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 17 Spain Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 18 Spain Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 19 Asia Pacific Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 20 Asia Pacific Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 21 Japan Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 22 Japan Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 23 China Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 24 China Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 25 India Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 26 India Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 27 South Korea Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 28 South Korea Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 29 Latin America Inhalable DrugsMarket, By Product, 2014 - 2026 (USD Million)
Table 30 Latin America Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 31 Brazil Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 32 Brazil Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 33 Mexico Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 34 Mexico Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 35 Argentina Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 36 Argentina Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 37 Middle East & Africa Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 38 Middle East & Africa Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 39 Saudi Arabia Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 40 Saudi Arabia Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 41 South Africa Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 42 South Africa Inhalable Drugs, By Application, 2014 - 2026 (USD Million)
Table 43 UAE Inhalable Drugs Market, By Product, 2014 - 2026 (USD Million)
Table 44 UAE Inhalable Drugs, By Application, 2014 - 2026 (USD Million)

List of Figures

Fig. 1 Inhalable drugs market snapshot
Fig. 2 Inhalable drugs market segmentation
Fig. 3 Inhalable drugs market driver impact
Fig. 4 Market restraint relevance analysis (Current & future impact)
Fig. 5 Key market opportunities
Fig. 6 SWOT analysis, by factor (Political & legal, economic, and technological)
Fig. 7 Porter's five forces analysis
Fig. 8 Inhalable drugs market, Product outlook: Key takeaways
Fig. 9 Inhalable Drugs Market: Product movement analysis
Fig. 10 Aerosol inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 11 Dry powder formulation inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 12 Spray inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 13 Inhalable drugs market, application outlook: Key takeaways
Fig. 14 Inhalable drugs market: Application movement analysis
Fig. 15 Respiratory diseases inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 16 Non-respiratory diseases inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 17 Regional market place: Key takeaways
Fig. 18 Inhalable drugs market: Regional movement analysis
Fig. 19 North America
Fig. 20 North America inhalable drugs market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 21 U.S.
Fig. 22 U.S. inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 23 Canada
Fig. 24 Canada inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 25 Europe
Fig. 26 Europe inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 27 Germany
Fig. 28 Germany inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 29 U.K.
Fig. 30 U.K. inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 31 France
Fig. 32 France inhalable drugs market, 2014 - 2026
Fig. 33 Italy
Fig. 34 Italy inhalable drugs market, 2014 - 2026
Fig. 35 Spain
Fig. 36 Spain inhalable drugs market, 2014 - 2026
Fig. 37 Asia Pacific
Fig. 38 Asia Pacific inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 39 Japan
Fig. 40 Japan inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 41 China
Fig. 42 China inhalable drugs market, 2014 - 2026
Fig. 43 India
Fig. 44 India inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 45 South Korea
Fig. 46 South Korea inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 47 Latin America
Fig. 48 Latin America inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 49 Brazil
Fig. 50 Brazil inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 51 Mexico
Fig. 52 Mexico inhalable drugs market, 2014 - 2026 (USD Million)
Fig. 53 Argentina
Fig. 54 Argentina inhalable drugs market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 55 Middle East & Africa
Fig. 56 Middle East and Africa inhalable drugs market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 57 South Africa
Fig. 58 South Africa inhalable drugs market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 59 South Africa
Fig. 60 Saudi Arabia inhalable drugs market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 61 UAE
Fig. 62 UAE inhalable drugs market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 63 Strategy framework